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Abstract
Background: Myotonic dystrophy type 2 is a multisystem disorder with both neurological and non-neurological
signs and symptoms. Seizures are not a commonly associated neurological feature of this disorder.
Case presentation: A 57-year-old white American man presented with a long history of clinical and
electrophysiological features of a myotonic disorder. He also developed multiple episodes of focal seizures
and underwent a series of investigations which showed no structural or metabolic etiology. Genetic testing
revealed that he had an expansion mutation in CCHC-type zinc finger, nucleic acid binding protein gene confirming the
diagnosis of myotonic disorder type 2 and carried a mutation in the chloride voltage-gated channel 1 gene.
Conclusions: We report a rare association between myotonic dystrophy type 2 and a seizure disorder. The
pathophysiology of a possible relationship between these two neurological conditions is discussed.
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Background
The myotonic dystrophies are a group of genetic disor-
ders characterized by both neurological and non-
neurological manifestations [1]. Myotonic dystrophy type
1 (DM1) is caused by (CTG)n repeat expansions in 3′
untranslated region of the dystrophia myotonica protein
kinase (DMPK) gene, while myotonic dystrophy type 2
(DM2) is caused by a tetranucleotide repeat (CCTG)n in
the first intron of the CCHC-type zinc finger, nucleic acid
binding protein (CNBP) gene.
Progressive weakness and myotonia are common
neurological features in both DM1 and DM2; however,
seizures are not typically associated with either of these
disorders. We report the case of a patient with genetic-
ally confirmed myotonic dystrophy co-segregating with a
chloride voltage-gated channel 1 (CLCN1) gene mutation
and partial seizures.
Case presentation
We describe the case of a 57-year-old white American
man with a history of weakness who presented for gen-
etic confirmation of a myotonic disorder. He had been
evaluated and diagnosed as having a myotonic disorder
at age 27 years when he presented for complaints of
stiffness. This diagnosis was made after an electromyog-
raphy (EMG) test was performed. Over the ensuing 30
years, he developed proximal muscle weakness more
marked in his legs than arms with no other significant
neurological complaints. A neurological examination at
age 57 years showed no abnormalities of his mental
status; a cranial nerve examination and cerebellar
testing showed no abnormalities, and a sensory exam-
ination testing proprioception, vibration, light touch,
and pin prick sensibility showed no abnormalities. He
had normoactive reflexes with flexor plantar re-
sponses. An examination of power revealed Medical
Research Council (MRC) grade 4/5 weakness in tests
of internal and external rotation, and in deltoid, biceps,
and hip flexion. In the remaining muscles, he had normal
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strength. His muscle bulk was normal and although he
had no percussion myotonia, there was a delay in releasing
a handshake consistent with action-induced myotonia.
Tests of gait were normal.
There was no family history of anyone with a similar
disorder but his father died at age 56 years from heart
disease and there was no other history available on the
paternal side. His paternal ancestors came from Romania
but originally were of German descent. His mother died
at age 94 years from breast cancer and had no clinical
features to suggest she was affected by a myotonic
disorder.
Multiple recent EMGs had been performed showing
the presence of myotonic discharges with no convincing
evidence of myopathy. Genetic testing was performed
confirming a diagnosis of DM2, an additional mutation
was also detected in his CLCN1 gene (refer to Genetic
testing subsection).
He was seen in follow up and several years after
the confirmation of the diagnosis, he presented with
four episodes of mild weakness of his right arm, leg
and face associated with numbness and tingling in
the same distribution. He also developed slurring of
his speech during these episodes which lasted for approxi-
mately 2 minutes following a return to his baseline in 10
minutes. He initially went to our emergency room where
a diagnosis of transient ischemic attack was made and in-
vestigations were performed including a cerebral magnetic
resonance imaging and magnetic resonance angiography,
carotid ultrasound, and an echocardiogram. All these tests
and routine serum chemistries were normal or negative.
These episodes recurred three more times over a course
of 6 months. The episodes were stereotypical with no clear
initiating event and with full recovery to baseline within
10 minutes. A repeat neurological examination showed no
significant change from that initially performed. A routine
electroencephalogram (EEG) was done 1 month after the
last episode showing slowing in his left cerebral hemi-
sphere with no other abnormality detected. He was diag-
nosed with focal seizures. Approximately 4 months after
the last episode, a repeat routine EEG was done and was
normal. This was followed up with a 48-hour EEG record-
ing which was also normal. Over the course of the next 24
months, no further seizure episodes were noted without
him taking an anticonvulsant medication.
Genetic testing
Genetic testing was performed by a commercial com-
pany and analysis for expansions in the DMNK and
CNBP genes. However, since he had a prior diagnosis of
myotonia congenita, analysis of the skeletal muscle
chloride channel, CLCN1 gene was also performed. The
results showed no genetic evidence for DM1; testing for
DM2 showed a mutant-expanded intronic allele of
greater than 372 CCTG repeats with the wild-type allele
of 140 repeats in CNBP gene. In addition, a heterozygous
mutation in the CLCN1 was also detected, rs149729531,
c.501C>G, p.F167L.
Discussion
Our patient has genetically confirmed DM2 with an
associated CLCN1 mutation. It is likely that he inher-
ited the mutation from his father who died relatively
young and for whom there is little history available.
Alternatively, it may represent a spontaneous muta-
tion. Mutations in the CLCN1 gene can cause either
autosomal dominant Thomsen’s type myotonia or re-
cessive Becker’s type. It is interesting that a number
of patients with DM2 co-segregating heterozygous re-
cessive mutations in CLCN1 have been reported [2].
It has been suggested that the patients with DM2
without the associated CLCN1 mutations are less
likely to seek medical attention perhaps indicating
that in them, the disease is less phenotypically severe.
Recently there have been two case reports of patients
with DM who had seizures. The first is that of a pa-
tient with the clinical features of DM and epilepsy
but without genetic confirmation of diagnosis [3]. In
another study, a patient with genetically confirmed
DM2 was noted to have a long history of generalized
epilepsy [4]. The episodes experienced by our patient
are most consistent with focal seizures without im-
pairment of consciousness or awareness [5]. Our pa-
tient is the first to be described with partial seizures
associated with mutations in both the CNBP and
CLCN1 genes. The specific mutation in the CLCN1
gene in our patient has been previously reported in
individuals with Becker’s type or recessive generalized
myotonia [6].
There are several links between myotonic disorders
and epilepsy. Both are episodic disorders and the
treatment of myotonia can include anti-epilepsy medi-
cations [7]. The CNBP gene is expressed in both per-
ipheral and central nervous system tissues [1]. Until
recently, it was thought that the chloride channel
protein 1 (ClC-1) protein, the product of the CLCN1
gene, was not expressed in brain tissue. However, a
recent report suggests that CLCN1 is expressed in the
mouse thalamus and cortex [8]. In this study, in
addition to this animal data, a patient with epilepsy is
presented. A mutation in the CLCN1 gene is reported
and it is hypothesized that this disease-producing mu-
tation is the cause of the seizure disorder in this pa-
tient [9]. This supports other research that indicates
that there is significant variability in CLCN1 tran-
scripts in both muscle and brain tissues that could
contribute to the phenotypic variability observed in
patients with myotonic disorders [8, 10].
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In our patient, it is possible that the mutations in
CNBP or CLCN1 genes alone or in combination are in-
volved in the pathophysiology of the seizure.
Conclusions
This report describes the rare case of a patient with
mutations in CNBP and CLCN1 genes presenting with
DM2 and a seizure disorder. This co-occurrence of
these two episodic disorders could indicate a shared
pathophysiology.
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